Receptor-mediated endocytosis and brain delivery of therapeutic biologics

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Xiao, Guangqing ^a   Gan, Liang Shang ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADALIMUMAB; ANGIOPEPTIN; ANGIOPEPTIN 2; APROTININ; CELL SURFACE RECEPTOR; ERYTHROPOIETIN; FC RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN G; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RECEPTOR; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; NONHUMAN; PH; PHAGOLYSOSOME; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIA; TRANSCYTOSIS;

EID: 84880161805     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/703545     Document Type: Review

References (107)

1. Blumling J. P. III, Silva G. A., Targeting the brain: advances in drug delivery. Current Pharmaceutical Biotechnology 2012 13 2417 2426 10.2174/138920112803341833
2. Gabathuler R., Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease 2010 37 1 48 57 2-s2.0-70449529637 10.1016/j.nbd.2009.07.028
3. Demeule M., Currie J., Bertrand Y., Ché C., Nguyen T., Régina A., Gabathuler R., Castaigne J., Béliveau R., Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. Journal of Neurochemistry 2008 106 4 1534 1544 2-s2.0-48749095941 10.1111/j.1471-4159.2008.05492.x
4. Demeule M., Regina A., Ché C., Poirier J., Nguyen T., Gabathuler R., Castaigne J., Béliveau R., Identification and design of peptides as a new drug delivery system for the brain. Journal of Pharmacology and Experimental Therapeutics 2008 324 3 1064 1072 2-s2.0-40849085422 10.1124/jpet.107.131318
5. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., Jiang X., Yao L., Chen J., Chen H., Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011 32 31 8010 8020 2-s2.0-80051817418 10.1016/j.biomaterials.2011.07.004
6. Huile G., Shuaiqi P., Zhi Y., Shijie C., Chen C., Xinguo J., Shun S., Zhiqing P., Yu H., A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 2011 32 33 8669 8675 2-s2.0-80052961350 10.1016/j.biomaterials. 2011.07.069
7. Muruganandam A., Tanha J., Narang S., Stanimirovic D., Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. The FASEB Journal 2002 16 2 240 242 2-s2.0-0036480118
8. Tanha J., Muruganandam A., Stanimirovic D., Phage display technology for identifying specific antigens on brain endothelial cells. Methods in Molecular Medicine 2003 89 435 449 2-s2.0-0642342122
9. Haqqani A. S., Caram-Salas N., Ding W., Brunette E., Delaney C. E., Baumann E., Boileau E., Stanimirovic D., Multiplexed Evaluation of Serum and CSF Pharmacokinetics of Brain-Targeting Single-Domain Antibodies Using a NanoLC-SRM-ILIS Method. Molecular Pharmaceutics 2013 10 5 1542 1556 10.1021/mp3004995
10. Boado R. J., Hui E. K., Lu J. Z., Pardridge W. M., Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metabolism and Disposition 2012 40 2021 2025 10.1124/dmd.112.046375
11. Pardridge W. M., Boado R. J., Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods in Enzymology 2012 503 269 292 2-s2.0-84855597543 10.1016/B978-0-12-396962-0.00011-2
12. Pardridge W. M., Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjugate Chemistry 2008 19 7 1327 1338 2-s2.0-47749105642 10.1021/bc800148t
13. Dumont J. A., Liu T., Low S. C., Zhang X., Kamphaus G., Sakorafas P., Fraley C., Drager D., Reidy T., McCue J., Franck H. W. G., Merricks E. P., Nichols T. C., Bitonti A. J., Pierce G. F., Jiang H., Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophiliaA mice and dogs. Blood 2012 119 13 3024 3030 2-s2.0-84859192874 10.1182/blood-2011-08-367813
14. Yeung Y. A., Leabman M. K., Marvin J. S., Qiu J., Adams C. W., Lien S., Starovasnik M. A., Lowman H. B., Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. Journal of Immunology 2009 182 12 7663 7671 2-s2.0-67649207267 10.4049/jimmunol.0804182
15. Caram-Salas N., Boileau E., Farrington G. K., Garber E., Brunette E., Abulrob A., Stanimirovic D., In vitro and in vivo methods for assessing fcrn-mediated reverse transcytosis across the blood-brain barrier. Methods in Molecular Biology 2011 763 383 401 2-s2.0-80054729360 10.1007/978-1-61779-191-8- 26
16. Zhang Y., Pardridge W. M., Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. Journal of Neuroimmunology 2001 114 1-2 168 172 2-s2.0-0035283233 10.1016/S0165-5728(01)00242-9
17. Abuqayyas L., Balthasar J. P., Investigation of the role of Fc γ R and FcRn in mAb distribution to the brain. Molecular Pharmaceutics 2013 10 5 1505 1513
18. Garg A., Balthasar J. P., Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS Journal 2009 11 3 553 557 2-s2.0-73349086530 10.1208/s12248-009-9129-9
19. Conner S. D., Schmid S. L., Regulated portals of entry into the cell. Nature 2003 422 6927 37 44 2-s2.0-0037422066 10.1038/nature01451
20. Lin J. H., Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Current Drug Metabolism 2009 10 7 661 691 2-s2.0-72949106918 10.2174/138920009789895499
21. Underhill D. M., Goodridge H. S., Information processing during phagocytosis. Nature Reviews Immunology 2012 12 492 502 10.1038/nri3244
22. Mayor S., Pagano R. E., Pathways of clathrin-independent endocytosis. Nature Reviews Molecular Cell Biology 2007 8 8 603 612 2-s2.0-34547114456 10.1038/nrm2216
23. McMahon H. T., Boucrot E., Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nature Reviews Molecular Cell Biology 2011 12 8 517 533 2-s2.0-79960720320 10.1038/nrm3151
24. Nabi I. R., Le P. U., Caveolae/raft-dependent endocytosis. Journal of Cell Biology 2003 161 4 673 677 2-s2.0-0037684840 10.1083/jcb.200302028
25. Kiss A. L., Caveolae and the regulation of endocytosis. Advances in Experimental Medicine and Biology 2012 729 14 28 2-s2.0-84859805944 10.1007/978-1-4614-1222-9-2
26. Sato K., Nagai J., Mitsui N., Ryoko Yumoto R. Y., Takano M., Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sciences 2009 85 23-26 800 807 2-s2.0-70649111219 10.1016/j.lfs.2009.10.012
27. Kruth H. S., Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles. Current Opinion in Lipidology 2011 22 5 386 393 2-s2.0-80052703870 10.1097/MOL.0b013e32834adadb
28. Kruth H. S., Jones N. L., Huang W., Zhao B., Ishii I., Chang J., Combs C. A., Malide D., Zhang W., Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. Journal of Biological Chemistry 2005 280 3 2352 2360 2-s2.0-12544258729 10.1074/jbc.M407167200
29. Jahn M. R., Nawroth T., Futterer S., Wolfrum U., Kolb U., Langguth P., Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells. Molecular Pharmaceutics 2012 9 1628 1637 10.1021/mp200628u
30. Hervé F., Ghinea N., Scherrmann J. M., CNS delivery via adsorptive transcytosis. AAPS Journal 2008 10 3 455 472 2-s2.0-57149110011 10.1208/s12248-008-9055-2
31. Kato M., Kamiyama H., Okazaki A., Kumaki K., Kato Y., Sugiyama Y., Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology and Experimental Therapeutics 1997 283 2 520 527 2-s2.0-0030778338
32. van Lammerts Bueren J. J., Bleeker W. K., Bøgh H. O., Houtkamp M., Schuurman J., van de Winkel J. G. J., Parren P. W. H. I., Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Research 2006 66 15 7630 7638 2-s2.0-33747876762 10.1158/0008-5472.CAN- 05-4010
33. Khorev O., Stokmaier D., Schwardt O., Cutting B., Ernst B., Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorganic and Medicinal Chemistry 2008 16 9 5216 5231 2-s2.0-43049125473 10.1016/j.bmc.2008.03.017
34. Macedo-Ramos H., Campos F. S. O., Carvalho L. A., Ramos I. B., Teixeira L. M., De Souza W., Cavalcante L. A., Baetas-da-Cruz W., Olfactory ensheathing cells as putative host cells for Streptococcus pneumoniae: evidence of bacterial invasion via mannose receptor-mediated endocytosis. Neuroscience Research 2011 69 4 308 313 2-s2.0-79951942911 10.1016/j.neures.2010.12.015
35. Taylor M. E., Structure and function of the macrophage mannose receptor. Results and Problems in Cell Differentiation 2001 33 105 121 2-s2.0-0035227746
36. Biessen E. A. L., van Teijlingen M., Vietsch H., Barrett-Bergshoeff M. M., Bijsterbosch M. K., Rijken D. C., van Berkel T. J. C., Kuiper J., Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997 95 1 46 52 2-s2.0-0031014592
37. Daniels T. R., Delgado T., Helguera G., Penichet M. L., The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology 2006 121 2 159 176 2-s2.0-33750019824 10.1016/j.clim.2006. 06.006
38. Anabousi S., Bakowsky U., Schneider M., Huwer H., Lehr C., Ehrhardt C., In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. European Journal of Pharmaceutical Sciences 2006 29 5 367 374 2-s2.0-33750690503 10.1016/j.ejps.2006.07.004
39. Singh M., Atwal H., Micetich R., Transferrin directed delivery of adriamycin to human cells. Anticancer Research 1998 18 3 1423 1427 2-s2.0-0031830132
40. den Broeder A., van de Putte L. B. A., Rau R., Schattenkirchner M., van Riel P. L. C. M., Sander O., Binder C., Fenner H., Bankmann Y., Velagapudi R., Kempeni J., Kupper H., A single dose, placebo controlled study of the fully human anti-tumor necrosis factor- α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. Journal of Rheumatology 2002 29 11 2288 2298 2-s2.0-0036844296
41. Bell R. D., Sagare A. P., Friedman A. E., Bedi G. S., Holtzman D. M., Deane R., Zlokovic B. V., Transport pathways for clearance of human Alzheimer's amyloid β -peptide and apolipoproteins E and J in the mouse central nervous system. Journal of Cerebral Blood Flow and Metabolism 2007 27 5 909 918 2-s2.0-34247506244 10.1038/sj.jcbfm.9600419
42. Ito S., Ohtsuki S., Terasaki T., Functional characterization of the brain-to-blood efflux clearance of human amyloid- β peptide (1-40) across the rat blood-brain barrier. Neuroscience Research 2006 56 3 246 252 2-s2.0-33750017850 10.1016/j.neures.2006.07.006
43. Shibata M., Yamada S., Kumar S. R., Calero M., Bading J., Frangione B., Holtzman D. M., Miller C. A., Strickland D. K., Ghiso J., Zlokovic B. V., Clearance of Alzheimer's amyloid- β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 2000 106 12 1489 1499 2-s2.0-0034521392
44. Hussain M. M., Strickland D. K., Bakillah A., The mammalian low-density lipoprotein receptor family. Annual Review of Nutrition 1999 19 141 172 2-s2.0-0032802253 10.1146/annurev.nutr.19.1.141
45. Moestrup S. K., Cui S., Vorum H., Bregengård C., Bjørn S. E., Norris K., Gliemann J., Christensen E. I., Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. Journal of Clinical Investigation 1995 96 3 1404 1413 2-s2.0-0029151692
46. Dehouck M. P., Jolliet-Riant P., Bree F., Fruchart J. C., Cecchelli R., Tillement J. P., Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. Journal of Neurochemistry 1992 58 5 1790 1797 2-s2.0-0026719204 10.1111/j.1471-4159.1992.tb10055.x
47. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., Qian Y., Sun X., Jiang X., The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012 33 11 3324 3333 2-s2.0-84856560779 10.1016/j.biomaterials.2012.01.025
48. Kurzrock R., Gabrail N., Chandhasin C., Moulder S., Smith C., Brenner A., Sankhala K., Mita A., Elian K., Bouchard D., Sarantopoulos J., Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2012 11 2 308 316 2-s2.0-84856874126 10.1158/1535-7163.MCT-11-0566
49. Huang S., Li J., Han L., Liu S., Ma H., Huang R., Jiang C., Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 2011 32 28 6832 6838 2-s2.0-79960561767 10.1016/j.biomaterials. 2011.05.064
50. Gao H., Qian J., Cao S., Yang Z., Pang Z., Pan S., Fan L., Xi Z., Jiang X., Zhang Q., Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012 33 20 5115 5123 2-s2.0-84860387204 10.1016/j.biomaterials.2012.03.058
51. Xin H., Sha X., Jiang X., Chen L., Law K., Gu J., Chen Y., Wang X., Fang X., The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε -caprolactone) nanoparticles. Biomaterials 2012 33 5 1673 1681 2-s2.0-83355162386 10.1016/j.biomaterials.2011.11.018
52. Boado R. J., Zhou Q., Lu J. Z., Hui E. K., Pardridge W. M., Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Molecular Pharmaceutics 2010 7 1 237 244 2-s2.0-76249087751 10.1021/mp900235k
53. Huwyler J., Pardridge W. M., Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. Journal of Neurochemistry 1998 70 2 883 886 2-s2.0-0031912895
54. Pardridge W. M., Kang Y. S., Buciak J. L., Yang J., Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmaceutical Research 1995 12 6 807 816 2-s2.0-0029009048
55. Pardridge W. M., Buciak J. L., Friden P. M., Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. Journal of Pharmacology and Experimental Therapeutics 1991 259 1 66 70 2-s2.0-0025836586
56. Broadwell R. D., Baker-Cairns B. J., Friden P. M., Oliver C., Villegas J. C., Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Experimental Neurology 1996 142 1 47 65 2-s2.0-0030297155 10.1006/exnr.1996.0178
57. Zhang Y., Pardridge W. M., Rapid transferrin efflux from brain to blood across the blood-brain barrier. Journal of Neurochemistry 2001 76 5 1597 1600 2-s2.0-0035092097 10.1046/j.1471-4159.2001.00222.x
58. Lee H. J., Engelhardt B., Lesley J., Bickel U., Pardridge W. M., Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. Journal of Pharmacology and Experimental Therapeutics 2000 292 3 1048 1052 2-s2.0-0002595302
59. Fleischmann R., Baumgartner S. W., Weisman M. H., Liu T., White B., Peloso P., Long term safety of etanercept in elderly subjects with rheumatic diseases. Annals of the Rheumatic Diseases 2006 65 3 379 384 2-s2.0-33144490233 10.1136/ard.2005.035287
60. Sumbria R. K., Boado R. J., Pardridge W. M., Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein. Journal of Cerebral Blood Flow & Metabolism 2012 32 1933 1938
61. Boado R. J., Hui E. K., Lu J. Z., Zhou Q., Pardridge W. M., Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. Journal of Biotechnology 2010 146 1-2 84 91 2-s2.0-77249163613 10.1016/j.jbiotec.2010.01.011
62. Ferger B., Leng A., Mura A., Hengerer B., Feldon J., Genetic ablation of tumor necrosis factor-alpha (TNF- α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. Journal of Neurochemistry 2004 89 4 822 833 2-s2.0-2542475349 10.1111/j.1471-4159.2004. 02399.x
63. Zhou Q., Fu A., Boado R. J., Hui E. K., Lu J. Z., Pardridge W. M., Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. Molecular Pharmaceutics 2011 8 1 280 285 2-s2.0-79952932382 10.1021/mp1003515
64. Atwal J. K., Chen Y., Chiu C., Mortensen D. L., Meilandt W. J., Liu Y., Heise C. E., Hoyte K., Luk W., Lu Y., Peng K., Wu P., Rouge L., Zhang Y., Lazarus R. A., Scearce-Levie K., Wang W., Wu Y., Tessier-Lavigne M., Watts R. J., A therapeutic antibody targeting BACE1 inhibits amyloid- β production in vivo. Science Translational Medicine 2011 3 84 2-s2.0-79957452852 10.1126/scitranslmed.3002254 84ra43
65. Yu Y. J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J. M., Prabhu S., Watts R. J., Dennis M. S., Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine 2011 3 84 2-s2.0-79957439772 10.1126/scitranslmed. 3002230 84ra44
66. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A., Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996 380 6571 252 255 2-s2.0-13344277993 10.1038/380252a0
67. Kirik D., Georgievska B., Björklund A., Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nature Neuroscience 2004 7 2 105 110 2-s2.0-1642499508 10.1038/nn1175
68. Fu A., Zhou Q., Hui E. K., Lu J. Z., Boado R. J., Pardridge W. M., Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Research 2010 1352 208 213 2-s2.0-77956178352 10.1016/j.brainres.2010.06.059
69. Abulrob A., Sprong H., van Bergen en Henegouwen P., Stanimirovic D., The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. Journal of Neurochemistry 2005 95 4 1201 1214 2-s2.0-28244432240 10.1111/j.1471-4159.2005. 03463.x
70. Boado R. J., Hui E. K., Zhiqiang Lu J., Pardridge W. M., Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular trojan horse. Journal of Pharmacology and Experimental Therapeutics 2010 333 3 961 969 2-s2.0-77952329581 10.1124/jpet.109.165092
71. Al Sawaf S., Mayatepek E., Hoffmann B., Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. Journal of Inherited Metabolic Disease 2008 31 4 473 480 2-s2.0-50149108962 10.1007/s10545-008-0878-x
72. Wraith J. E., Scarpa M., Beck M., Bodamer O. A., De Meirleir L., Guffon N., Meldgaard Lund A., Malm G., van der Ploeg A. T., Zeman J., Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics 2008 167 3 267 277 2-s2.0-39149118050 10.1007/s00431-007-0635-4
73. Lu J. Z., Hui E. K., Boado R. J., Pardridge W. M., Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjugate Chemistry 2010 21 1 151 156 2-s2.0-74949139623 10.1021/bc900382q
74. Boado R. J., Pardridge W. M., Genetic engineering of IgG-glucuronidase fusion proteins. Journal of Drug Targeting 2010 18 3 205 211 2-s2.0-77949405266 10.3109/10611860903353362
75. Muyldermans S., Lauwereys M., Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. Journal of Molecular Recognition 1999 12 131 140
76. Haqqani A. S., Delaney C. E., Tremblay T. L., Sodja C., Sandhu J. K., Stanimirovic D. B., Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Barriers CNS 2013 10 1, article 4
77. van der Linden R. H. J., Frenken L. G. J., de Geus B., Harmsen M. M., Ruuls R. C., Stok W., De Ron L., Wilson S., Davis P., Verrips C. T., Comparison of physical chemical properties of llama V(HH) antibody fragments and mouse monoclonal antibodies. Biochimica et Biophysica Acta 1999 1431 1 37 46 2-s2.0-0032955291 10.1016/S0167-4838(99)00030-8
78. Brambell F. W. R., Hemmings W. A., Morris I. G., A theoretical model of γ -globulin catabolism. Nature 1964 203 4952 1352 1355 2-s2.0-0000146003 10.1038/2031352a0
79. Jones E. A., Waldmann T. A., The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. Journal of Clinical Investigation 1972 51 11 2916 2927 2-s2.0-0015421358
80. Israel E. J., Patel V. K., Taylor S. F., Marshak-Rothstein A., Sinister N. E., Requirement for a β 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. Journal of Immunology 1995 154 12 6246 6251 2-s2.0-0028980061
81. Simister N. E., Mostov K. E., An Fc receptor structurally related to MHC class I antigens. Nature 1989 337 6203 184 187 2-s2.0-0024529856
82. Israel E. J., Taylor S., Wu Z., Mizoguchi E., Blumberg R. S., Bhan A., Simister N. E., Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997 92 1 69 74 2-s2.0-0030880901
83. Schlachetzki F., Zhu C., Pardridge W. M., Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. Journal of Neurochemistry 2002 81 1 203 206 2-s2.0-0036079202 10.1046/j.1471-4159.2002.00840.x
84. Shah U., Dickinson B. L., Blumberg R. S., Simister N. E., Lencer W. I., Walker W. A., Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatric Research 2003 53 2 295 301 2-s2.0-0037317875 10.1203/01.PDR.0000047663.81816.E3
85. Yoshida M., Masuda A., Kuo T. T., Kobayashi K., Claypool S. M., Takagawa T., Kutsumi H., Azuma T., Lencer W. I., Blumberg R. S., IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Seminars in Immunopathology 2006 28 4 397 403 2-s2.0-33845390606 10.1007/s00281-006-0054-z
86. Akilesh S., Christianson G. J., Roopenian D. C., Shaw A. S., Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. Journal of Immunology 2007 179 7 4580 4588 2-s2.0-39549088649
87. Roopenian D. C., Akilesh S., FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology 2007 7 9 715 725 2-s2.0-34548229364 10.1038/nri2155
88. McCarthy K. M., Yoong Y., Simister N. E., Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. Journal of Cell Science 2000 113, part 7 1277 1285 2-s2.0-0034058526
89. Wani M. A., Haynes L. D., Kim J., Bronson C. L., Chaudhury C., Mohanty S., Waldmann T. A., Robinson J. M., Anderson C. L., Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant β 2-microglobulin gene. Proceedings of the National Academy of Sciences of the United States of America 2006 103 13 5084 5089 2-s2.0-33645531322 10.1073/pnas.0600548103
90. Israel E. J., Wilsker D. F., Hayes K. C., Schoenfeld D., Simister N. E., Increased clearance of IgG in mice that lack β 2-microglobulin: possible protective role of FcRn. Immunology 1996 89 4 573 578 2-s2.0-0029856774
91. Junghans R. P., Anderson C. L., The protection receptor for IgG catabolism is the β 2-microglobulin-containing neonatal intestinal transport receptor. Proceedings of the National Academy of Sciences of the United States of America 1996 93 11 5512 5516 2-s2.0-0029891262
92. Medesan C., Matesoi D., Radu C., Ghetie V., Ward E. S., Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1. Journal of Immunology 1997 158 5 2211 2217 2-s2.0-0031093498
93. Medesan C., Radu C., Kim J., Ghetie V., Ward E. S., Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. European Journal of Immunology 1996 26 10 2533 2536 2-s2.0-0029842013 10.1002/eji.1830261038
94. Vaughn D. E., Milburn C. M., Penny D. M., Martin W. L., Johnson J. L., Bjorkman P. J., Identification of critical IgG binding epitopes on the neonatal Fc receptor. Journal of Molecular Biology 1997 274 4 597 607 2-s2.0-0031566036 10.1006/jmbi.1997.1388
95. Wang W., Lu P., Fang Y., Hamuro L., Pittman T., Carr B., Hochman J., Prueksaritanont T., Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metabolism and Disposition 2011 39 9 1469 1477 2-s2.0-80052008224 10.1124/dmd.111.039453
96. Roopenian D. C., Christianson G. J., Sproule T. J., Brown A. C., Akilesh S., Jung N., Petkova S., Avanessian L., Choi E. Y., Shaffer D. J., Eden P. A., Anderson C. L., The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. Journal of Immunology 2003 170 7 3528 3533 2-s2.0-0037379288
97. Vincent K. J., Zurini M., Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnology Journal 2012 7 1444 1450 10.1002/biot.201200250
98. Dall'Acqua W. F., Kiener P. A., Wu H., Properties of Human IgG1s engineered for enhanced binding to the neonatal Fc Receptor (FcRn). Journal of Biological Chemistry 2006 281 33 23514 23524 2-s2.0-33747631571 10.1074/jbc.M604292200
99. Hinton P. R., Xiong J. M., Johlfs M. G., Tang M. T., Keller S., Tsurushita N., An engineered human IgG1 antibody with longer serum half-life. Journal of Immunology 2006 176 1 346 356 2-s2.0-29644434678
100. Mikulska J. E., The neonatal receptor Fc gamma(FcRn)-structure and function. Postepy Higieny i Medycyny Doswiadczalnej 2001 55 4 487 511 2-s2.0-0035237420
101. Hansen R. J., Balthasar J. P., Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis and Haemostasis 2002 88 6 898 899 2-s2.0-0036918050
102. Bitonti A. J., Dumont J. A., Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Advanced Drug Delivery Reviews 2006 58 9-10 1106 1118 2-s2.0-33750699277 10.1016/j.addr.2006.07.015
103. Deane R., Sagare A., Hamm K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D. M., Zlokovic B. V., IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. Journal of Neuroscience 2005 25 50 11495 11503 2-s2.0-30844472909 10.1523/JNEUROSCI.3697-05.2005
104. Peters R. T., Toby G., Lu Q., Liu T., Kulman J. D., Low S. C., Bitonti A. J., Pierce G. F., Biochemical and functional characterization of a recombinant monomeric Factor VIII-Fc fusion protein. Journal of Thrombosis and Haemostasis 2013 11 1 132 141
105. Sockolosky J. T., Tiffany M. R., Szoka F. C., Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proceedings of the National Academy of Sciences of the United States of America 2012 109 16095 16100 10.1073/pnas.1208857109
106. Yu M., Du F., Ise H., Zhao W., Zhang Y., Yu Y., Yao F., Yang J., Akaike T., Preparation and characterization of a VEGF-Fc fusion protein matrix for enhancing HUVEC growth. Biotechnology Letters 2012 34 1765 1771 10.1007/s10529-012-0959-7
107. Manco-Johnson M. J., Abshire T. C., Shapiro A. D., Riske B., Hacker M. R., Kilcoyne R., Ingram J. D., Manco-Johnson M. L., Funk S., Jacobson L., Valentino L. A., Hoots W. K., Buchanan G. R., Dimichele D., Recht M., Brown D., Leissinger C., Bleak S., Cohen A., Mathew P., Matsunaga A., Medeiros D., Nugent D., Thomas G. A., Thompson A. A., McRedmond K., Soucie J. M., Austin H., Evatt B. L., Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. The New England Journal of Medicine 2007 357 6 535 544 2-s2.0-34547757915 10.1056/NEJMoa067659